Mark Drugs Limited - Company Profile

It is a pharma public limited company based in Na, Telangana, India, established in 1995.
1995 Na, Telangana, India Active
Last Updated:
Access Report
About Mark Drugs Limited

Mark Drugs Limited, a active public limited company, was established on 18 January 1995 in Na, Telangana, India. Engaging in drug formulation & development within the pharma sector, it holds CIN: U24239TG1995PLC019228. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹6.00 M and a paid-up capital of ₹4.21 M.

It upholds a active non-compliant status. Its leadership includes Anandam Dyavanapally (Director), Rajalingam Dyavanapalli (Director). It holds ₹3.60 M open charges and no settled loans. It is based at N-1-192,Viveknagarchikkadpally Hyderabad, Na, Telangana.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24239TG1995PLC019228

  • Registration Number

    019228

  • Incorporation Date

    18 January 1995

  • Authorized Capital

    ₹6.00 M

  • Paid-Up Capital

    ₹4.21 M

  • ROC Code

    Roc Hyderabad

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 6.00 M
  • Paid Up Capital ₹ 4.21 M
  • Company Age 31 Year, 30 Days
  • Open Charges ₹ 3.60 M
Company report

Mark Drugs Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Mark Drugs Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Mark Drugs Limited?
Current Directors
Name Designation Appointment Date Status
Anandam Dyavanapally Director 18 Jan 1995 Current
Rajalingam Dyavanapalli Director 18 Jan 1995 Current

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Mark Drugs.

Enhance accessibility to Mark Drugs's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.

Mark Drugs revenue growth over time
Mark Drugs profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
*******
*******
*******
*******
*******
Revenue from Operations
*******
*******
*******
*******
*******
*******
Total Assets
*******
*******
*******
*******
*******
*******
Profit or Loss
*******
*******
*******
*******
*******
*******
Net Worth
*******
*******
*******
*******
*******
*******
EBITDA
*******
*******
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Mark Drugs?

Unlock access to Mark Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹3,600,000.00

Satisfied Charges

₹0

Charges Breakdown by Lending Institutions
  • Canara Bank : 0.36 Cr
Latest Charge Details
Date Lender Amount Status
11 Feb 1999 Canara Bank ₹1.80 M Open
22 Feb 1997 Canara Bank ₹1.80 M Open

Explore comprehensive loan charge details -

How Many Employees Work at Mark Drugs?

Unlock and access historical data on people associated with Mark Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Mark Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mark Drugs's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Mark Drugs
Recent Activity within the Organization
  • Charges

    The activity A charge with Canara Bank amounted to Rs. 1.80 M with Charge ID 90115779 was registered on 11 Feb 1999. was completed.

  • Charges

    A charge with Canara Bank amounted to Rs. 1.80 M with Charge ID 90115443 was registered on 22 Feb 1997. was recorded as a recent event.

  • Director Appointment

    The activity Anandam Dyavanapally was appointed as a Director was appointed as a Director on 18 Jan 1995 & has been associated with this company since 31 years 30 days . was completed.

  • Director Appointment

    Rajalingam Dyavanapalli was appointed as a Director was appointed as a Director on 18 Jan 1995 & has been associated with this company since 31 years 30 days . was recorded as a recent event.

  • Company Incorporation

    Mark Drugs Limited was registered on 18 Jan 1995 with Roc Hyderabad & aged 31 years 30 days as per MCA records. was recorded as a recent event.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Mark Drugs Limited?

The CIN of Mark Drugs Limited is U24239TG1995PLC019228.

Where is Mark Drugs Limited headquartered?

Mark Drugs Limited is headquartered at N-1-192,Viveknagarchikkadpally Hyderabad, Na, Telangana.

When was Mark Drugs Limited incorporated?

Mark Drugs Limited was incorporated on 18 January 1995.

Who are the current directors of Mark Drugs Limited?

The current directors of Mark Drugs Limited are

What is the primary industry of Mark Drugs Limited?

The primary industry of Mark Drugs Limited is Pharma.

Is Mark Drugs Limited a listed company?

Mark Drugs Limited is unlisted.

What is the capital structure of Mark Drugs Limited?

The authorized capital of Mark Drugs Limited is ₹6.00 M, and the paid-up capital is ₹4.21 M.

What is the compliance status of Mark Drugs Limited?

The compliance status of Mark Drugs Limited is Active Non-Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available